# Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy

> **NCT05031975** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 35 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05031975
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-02
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05031975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05031975, "Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05031975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*